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Introduction: Because of a lack of randomized trials, the role of 
postoperative radiotherapy (PORT) in thymomas has not been estab-
lished. This study evaluated the prognostic impact of the adjuvant 
treatment in surgically resected nonlocalized thymomas.
Methods: Patients diagnosed between 2000 and 2010 were identi-
fied from the Surveillance, Epidemiology, and End Results database 
(1973–2011 registry). Cases with localized or organ-confined tumors 
were not included. Propensity-matched analysis was conducted con-
sidering baseline characteristics.
Results: A total of 529 patients were identified. The median age was 57 
years (range, 18–86), and 345 (65%) patients received PORT. Before 
and after propensity score matching, overall survival (OS; p = 0.018 
and 0.008, respectively) and disease-specific survival (DSS; p = 0.007 
and 0.008, respectively) were better in the PORT group. In multivariate 
analyses of the matched population, no receipt of PORT induced poorer 
OS (hazard ratio [HR], 1.98; 95% confidence interval [CI], 1.27–3.09) 
and DSS (HR, 2.64; 95% CI, 1.32–5.29). Primary tumor extensions 
of adjacent organs or structures and further contiguous extensions 
also resulted in worse outcomes (p < 0.001 and equal to 0.039 for OS; 
p = 0.006 and 0.009 for DSS, respectively). In the subgroup analyses, 
PORT was associated with favorable OS in stages III and IV (p = 0.049 
and 0.012, respectively) and DSS in stage III (p = 0.005).
Conclusion: Regarding the independent prognostic significance of 
PORT, this population-based analysis demonstrates the survival ben-
efits of PORT in relation to nonlocalized thymomas. We recommend 
consideration of PORT in the poor prognostic subset of stages III to 
IV in the contemporary era.
Key Words: Thymoma, Adjuvant radiotherapy, Survival analysis, 
SEER program, Propensity score, Masaoka stages III and IV.
(J Thorac Oncol. 2015;10: 1357–1363)
Thymomas are a common primary malignancy in the anterior mediastinum.1 According to a nation-wide 
report, the incidence of thymoma is approximately 0.15 
per 100,000 person-years in the United States.2 Although 
the diagnosis and histologic features of thymomas and thy-
mic carcinomas were previously confused, their differen-
tial schema were published in 1999 by the World Health 
Organization (WHO) Consensus Committee.3 Masaoka 
staging was defined based on the primary tumor extension 
and the degree of involvement of the surrounding organs.4 
The classification of stages I to IV is related to the natural 
course of local invasiveness, accounting for its common 
use in clinical practices.
For the curative management of thymomas, maxi-
mal tumor resection is the mainstay treatment. The patterns 
of failure have mostly involved locoregional recurrences 
in accordance with recurred tumors in the mediastinum or 
extramediastinal pleura.5 Though postoperative radiotherapy 
(PORT) has been considered for enhancing postsurgical tumor 
control, there have been few randomized controlled trials to 
assess the role of PORT because of its rarity and slow growth. 
To date, the survival benefits of PORT have been controver-
sial, and receipt of the adjuvant treatment is still dependent 
on institutional policy. PORT is not recommended in organ-
confined stage I disease because of its excellent prognosis.6,7 
In stages II to IV, treatment indications are still unknown, 
and PORT is usually recommended in incompletely resected 
tumors.8,9 Concerning complete resection, several previous 
studies have reported a lack of association between PORT and 
patients’ mortality.10–12
A few years ago, several investigations evaluated 
the role of PORT in thymomas based on the Surveillance, 
Epidemiology, and End Results (SEER) database.13–16 
Although they obtained survival outcomes in favor of the 
receipt of PORT, its independent statistical significance was 
not clearly reported. This study explored the prognostic impact 
of PORT in patients with stages IIB to IV thymomas using the 
SEER registry. We excluded the stage I disease considering its 
long-term survival and limited role of PORT expected. Stage 
IIA with microscopic transcapsular invasion could not be dif-
ferentiated from stage I in the nation-wide data. Therefore, 
based on the SEER database, the present analysis defined 
“nonlocalized” tumors as the Masaoka stages IIB to IV.
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To minimize the selection bias in the receipt of PORT, 
propensity score matching was conducted, and the distribution 
of baseline clinicopathologic variables was balanced. This 
population-based study can provide insight into the therapeu-
tic role of PORT with modern radiotherapy (RT) techniques.
PATIENTS AND METHODS
Patients
This study used the SEER 18-Registry (1973–2011 data 
set) of the National Cancer Institute. SEER is an authoritative 
nation-wide cancer database in the United States.17 We used 
SEER*Stat software (version 8.1.5; National Institutes of 
Health, Bethesda, MD) to extract the cases from the database.
Cases with the primary site of the thymus were obtained 
using the variable of “primary site labeled,” and the histology of 
thymomas were determined by the International Classification 
of Diseases codes (8580, 8581, 8582, 8583, 8584, and 8585) 
with the behavior code “/3,” indicating thymomas of the type 
not otherwise specified, A, AB, B1, B2, and B3, respectively. 
Patients aged 18 years or more and diagnosed from 2000 to 
2010 were selected. Patients who had undergone primary surgi-
cal resection with or without PORT were identified using the 
variables of “radiation sequence with surgery,” “radiation,” and 
“reason no cancer-directed surgery.” Regarding the extent of 
surgical tumor resection, radical, total, simple or partial, and 
debulking surgery codes were selected. Simple/partial or total 
surgical resection was determined based on the extent of mac-
roscopic surgical removal, and debulking surgery was coded 
in cases with the surgery stated to be “debulking.” The SEER 
registry defined radical surgery as partial or total removal of the 
primary site with an en bloc resection (partial or total removal) 
of other organs. Patients with a survival time of 3 months or less 
were excluded in the analysis to rule out perioperative mortality.
Because patients’ stage information was unknown in 
SEER, the Masaoka stage was inferred from several exist-
ing variables, such as primary tumor extension, lymph node 
status, and SEER historic stage. The tumor extent codes 
“localized or organ-confined,” “adjacent connective tissue,” 
“adjacent organs or structures in the mediastinum,” and “fur-
ther contiguous extension” were in accordance with the local 
tumor invasiveness of stages I to IIA, IIB, III, and IV, respec-
tively.13 Positive lymph node disease or the “distant” status of 
the SEER stage was considered stage IV. However, the stages 
I and IIA or IVA and IVB could not be differentiated based 
on the SEER data. Nonlocalized thymomas were classified as 
stages IIB, III, or IV.
Propensity Score Matching
Because the patients were not randomized in the database, 
selection bias from baseline characteristics could influence the 
receipt of PORT. A propensity score is defined as the probability 
being assigned to PORT or non-PORT groups given the clini-
copathologic characteristics.18 In the calculation of the propen-
sity scores, the nonparsimonious logistic regression model was 
used considering predefined baseline covariates, including age 
at diagnosis, gender, race, marital status, other malignancies, 
tumor extent, lymph node status, and extent of surgery.19 Patients 
treated with PORT were matched to the others based on the cal-
culated scores with an algorithm of the nearest neighbor and 1:1 
matching without a specific caliper width or replacement.20
Statistical Analysis
The clinicopathologic variables were categorized. In 
this study, overall survival (OS) and disease-specific survival 
(DSS) were the primary and secondary outcomes of interest, 
respectively. The survival time was defined as the time interval 
between the diagnosis of thymomas and deaths. Kaplan–Meier 
analyses were conducted to estimate the survival outcomes 
before and after propensity score matching. Using a log-rank 
test, the survival differences between the PORT and non-PORT 
groups were compared. In the multivariate analyses of the 
matched population, the Cox proportional hazards model was 
used. Related clinicopathologic factors with p values of less 
than 0.1 in the univariate analyses were adjusted. Statistical sig-
nificances were declared when the two-sided p values were less 
than 0.05. All of the statistical analyses were performed with 
IBM SPSS Statistics 22.0 (IBM, Armonk, NY) and R version 
2.8.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient Characteristics
A total of 529 patients with thymomas were identi-
fied. The baseline patient characteristics are listed in Table 1. 
The median age was 57 years (range, 18–86), and 280 (53%) 
patients were men. White patients comprised 67% of the entire 
population, and 331 (62%) patients were married. Sixty-eight 
(13%) patients were diagnosed with other malignancies. 
Primary tumors extending into the adjacent connective tis-
sue, adjacent organs or structures, and with further contiguous 
extensions were observed in 179 (34%), 281 (53%), and 69 
(13%) patients, respectively. The median tumor size was 6.5 cm 
(range, 0.3–23), and 121 (23%) patients had tumors of WHO 
histological classification type B3. Positive regional lymph 
node status was reported in 75 (14%) patients. Concerning the 
extent of surgical resection, 165 (31%), 220 (41%), 120 (23%), 
and 24 (5%) patients underwent radical surgery, total resection, 
simple or partial resection, and debulking surgery, respectively. 
Postoperative radiation was performed on 345 (65%) patients.
Survival Outcomes Before 
Propensity Score Matching
In the unmatched population (n = 529), 120 patients had 
died at the time of analysis. The 5-year and 7-year rates of 
OS were 81.8% and 72.5%, respectively. There were 50 death 
events caused by the diagnosis of thymomas, and the 5-year 
and 7-year rates of DSS were 91.5% and 87.6%, respectively.
Kaplan–Meier curves of OS and DSS according to the 
receipt of PORT are represented in Figure 1. For both OS and 
DSS, there were significant differences between the PORT 
and non-PORT groups in favor of the adjuvant treatment. The 
7-year OS rates of the PORT and non-PORT groups were 
75.8% and 66.1% (p = 0.018), respectively. The 7-year DSS 
rates of the PORT and non-PORT groups were 90.9% and 
81.2% (p = 0.007), respectively.
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Prognostic Significance After 
Propensity Score Matching
The matching process resulted in a balanced study pop-
ulation including PORT (n = 184) and non-PORT (n = 184) 
groups. Table 2 lists the detailed balances before and after 
propensity score matching. The absolute values of standard-
ized differences were reduced in all covariates, suggesting that 
potential selection bias in the receipt of PORT was minimized.
Figure 2 shows the Kaplan–Meier curves of OS and DSS 
in the matched population. The 7-year OS rates of the PORT 
and non-PORT groups were 78.5% and 66.1% (p = 0.008), 
respectively. For DSS, the 7-year rates of the two groups were 
92.1% and 81.2% (p = 0.008), respectively.
In the univariate analyses, the survival differences were 
assessed according to age at diagnosis (< 57 or ≥ 57 years), 
gender (men or women), race (white or other), marital status 
(married or not married), other malignancies (no or yes), pri-
mary tumor extension (adjacent connective tissue, organs and 
structures, or further contiguous extension), tumor size (<6.5 
or ≥6.5 cm), WHO histological classification (nontype B3 or 
type B3), regional lymph node status (negative or positive), 
extent of surgery (radical, total, simple/partial, or debulking 
surgery), and the receipt of PORT (yes or no). Age (p < 0.001), 
primary tumor extension (p = 0.004), and PORT (p = 0.008) 
were associated factors of OS. For DSS, primary tumor extent 
(p = 0.010) and PORT (p = 0.008) were prognostic.
Table 3 lists the results of the multivariate survival analy-
ses of the matched population. With the Cox proportional haz-
ards model of OS, an age of 57 years or more (versus age of <57 
years; hazard ratio [HR], 2.60; 95% confidence interval [CI], 
1.62–4.17), tumor invasion into adjacent organs/structures and 
further contiguous extensions (versus adjacent connective tis-
sue; HR, 2.69; 95% CI, 1.59–4.58 and HR, 2.15; 95% CI, 1.04–
4.43, respectively), and no receipt of PORT (versus receipt of 
PORT; HR, 1.98; 95% CI, 1.27–3.09) were poor prognostic fac-
tors. For DSS, tumor invasion into adjacent organs/structures 
and further contiguous extensions (versus adjacent connec-
tive tissue; HR, 3.55; 95% CI, 1.44–8.73 and HR, 4.15; 95% 
CI, 1.44–11.96, respectively) and no receipt of PORT (versus 
receipt of PORT; HR, 2.64; 95% CI, 1.32–5.29) were associ-
ated with shorter survival time.
Subgroup Analysis
Figure 3 represents OS and DSS curves in the subgroup 
analyses of the Masaoka stages IIB to IV. In the patients with 
stage IIB thymomas, no survival differences were observed in 
either OS or DSS according to the receipt of PORT (p = 0.738 
and 0.405, respectively). However, PORT resulted in better OS 
and DSS in stage III (p = 0.049 and 0.012, respectively). Superior 
OS was also observed for PORT in stage IV (p = 0.005), but 
DSS was not significantly different (p = 0.139).
DISCUSSION
There have been few randomized trials to assess the 
efficacy of PORT in thymomas. Because well-localized or 
organ-confined stage I thymoma has an excellent prognosis, 
the prognostic influence of PORT has been suggested to be 
limited in such a disease entity.7,21–23 To evaluate potential 
TABLE 1.  Baseline Characteristics of Surgically Resected 
Nonlocalized Thymoma Patients (N = 529)
Characteristics N (%)
Age (yrs)
 Median (range) 57 (18–86)
 <40 82 (16)
 40–49 99 (19)
 50–59 118 (22)
 60–69 124 (23)
 ≥70 106 (20)
gender
 Men 280 (53)
 Women 249 (47)
Race
 White 356 (67)
 Black 79 (15)
 Others 91 (17)
 Unknown 3 (1)
Marital status
 Married 331 (62)
 Not married 183 (35)
 Unknown 15 (3)
Other malignancy
 No 461 (87)
 Yes 68 (13)
Tumor extent
 Adjacent connective tissue 179 (34)
 Adjacent organs or structures 281 (53)
 Further contiguous extension 69 (13)
Tumor size (cm)
 Median (range) 6.5 (0.3–23)
 <6.5 212 (40)
 ≥6.5 252 (48)
 Unknown 65 (12)
WHO classification
 Not otherwise specified 142 (27)
 Type A 40 (7)
 Type AB 79 (15)
 Type B1 77 (15)
 Type B2 70 (13)
 Type B3 121 (23)
LN status
 Regional LN (−) 422 (80)
 Regional LN (+) or LNs, NOS 75 (14)
 Unknown 32 (6)
Extent of surgery
 Radical surgery 165 (31)
 Total resection 220 (41)
 Simple or partial resection 120 (23)
 Debulking surgery 24 (5)
Adjuvant external beam radiotherapy
 Yes 345 (65)
 No 184 (35)
WHO, World Health Organization; LN, lymph node; NOS, not otherwise specified.
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survival differences according to the receipt of PORT, this 
SEER-based analysis targeted nonlocalized tumors diagnosed 
and treated in the contemporary era.
Until now, several SEER-based studies have evaluated 
the role of PORT in thymomas.13–16 However, this study is 
distinguishable in that propensity score matching was firstly 
FIGURE 1.  Comparison of overall survival (A) 
and disease-specific survival (B) according to 
the receipt of postoperative radiotherapy before 
propensity score matching. PORT, postoperative 
radiotherapy.
TABLE 2.  Patient, Tumor, and Treatment Characteristics Before and After Propensity Score Matching
Variables
Before Propensity Score Matching After Propensity Score Matching
PORT (+) 
(N = 345)
PORT (−) 
(N = 184)
Standardized 
Difference
PORT (+) 
(N = 184)
PORT (−) 
(N = 184)
Standardized 
Difference
Age (yrs)
 <40 56 (16) 26 (14) 0.116 29 (16) 26 (14) 0.050
 40–49 61 (17) 38 (21) 34 (18) 38 (21)
 50–59 85 (25) 33 (18) 36 (20) 33 (18)
 60–69 85 (25) 39 (21) 46 (25) 39 (21)
 ≥70 58 (17) 48 (26) 39 (21) 48 (26)
gender
 Men 183 (53) 97 (53) 0.007 97 (53) 97 (53) < 0.001
 Women 162 (47) 87 (47) 87 (47) 87 (47)
Race
 White 232 (67) 124 (67) −0.077 132 (72) 124 (67) 0.036
 Black 45 (13) 34 (18) 22 (12) 34 (18)
 Others 66 (19) 25 (14) 30 (16) 25 (14)
 Unknown 2 (1) 1 (1) 0 (0) 1 (1)
Marital status
 Married 226 (66) 105 (57) 0.174 104 (56) 105 (57) −0.010
 Not married 111 (32) 72 (39) 73 (40) 72 (39)
 Unknown 8 (2) 7 (4) 7 (4) 7 (4)
Other malignancy
 No 296 (86) 165 (90) −0.127 166 (90) 165 (90) 0.018
 Yes 49 (14) 19 (10) 18 (10) 19 (10)
Tumor extent
 Adjacent connective tissue 108 (31) 71 (39) −0.108 66 (36) 71 (39) −0.016
 Adjacent organs or structures 192 (56) 89 (48) 97 (53) 89 (48)
 Further contiguous extension 45 (13) 24 (13) 21 (11) 24 (13)
LN status
 Regional LN (−) 280 (81) 142 (77) 0.117 142 (77) 142 (77) 0.035
 Regional LN (+) or LNs, NOS 48 (14) 27 (15) 31 (17) 27 (15)
 Unknown 17 (5) 15 (8) 11 (6) 15 (8)
Extent of surgery
 Debulking surgery 19 (6) 5 (3) −0.087 9 (5) 5 (3) 0.032
 Simple/partial surgical resection 70 (20) 50 (27) 43 (23) 50 (27)
 Total surgical resection 148 (43) 72 (39) 84 (46) 72 (39)
 Radical surgery 108 (31) 57 (31) 48 (26) 57 (31)
PORT, postoperative radiotherapy; LN, lymph node; NOS, not otherwise specified.
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used in relation to the potential selection bias in the receipt 
of PORT. From the matching process with patient, tumor, 
and treatment-related covariates, the well-balanced PORT 
and non-PORT groups were obtained.24 Because prior studies 
have mostly analyzed patients diagnosed before the 2000s, the 
present survival outcomes of patients diagnosed in the 2000s 
are updated results reflecting recent RT techniques. To assess 
patients’ Masaoka stage, this study summarized the informa-
tion of SEER-based variables. Nonlocalized thymomas were 
classified into stages IIB, III, or IV in the SEER data.
In our results, OS and DSS were longer in the PORT 
group both before and after the propensity score matching. 
Multivariate analyses of the matched patients showed the 
independent poor prognostic impacts of older age (≥57 years), 
more extensive primary tumor extensions (adjacent organs or 
structures and further contiguous extensions), and no receipt 
of PORT on OS, and the tumor extensions and PORT were 
also significantly associated with DSS. In the subgroup analy-
ses according to Masaoka stage, PORT significantly improved 
OS in stages III to IV and DSS in stage III, whereas there were 
no OS and DSS differences between the PORT and non-PORT 
groups in stage IIB.
The need for PORT has not been established in stage II 
thymomas. Singhal et al25 reported survival outcomes of 70 
patients with completely resected stages I to II thymomas 
and failed to show PORT-induced survival differences. In a 
retrospective study of 62 patients with completely resected 
stage II tumors,26 there was no significant difference in the 
proportion of recurrences either with or without PORT 
(p = 0.15). Furthermore, in a population-based investigation 
using the British Columbia Cancer Agency Registry, there was 
no difference in OS or freedom from recurrence according to 
the receipt of PORT.27 In this study, the propensity-matched 
subgroup analyses indicated no effects of PORT on both OS 
and DSS in stage IIB thymomas. Considering the less invasive 
nature of stage IIA, which was not included in the analysis, we 
demonstrate that the survival advantage of PORT might not be 
expected in stage II thymomas.
In addition, the prognostic impact of PORT in stage III 
has been controversial. Weksler et al16 analyzed 499 patients 
with stage III thymomas using the SEER database. No receipt 
of PORT resulted in a worse prognosis in DSS (p = 0.049) 
in the multivariate analysis, whereas there was no statistical 
significance in OS (p = 0.493). Although the difference in 
cause-specific mortality was considered notable, the PORT 
group included more patients with younger ages or who have 
undergone debulking surgery. More recently, a retrospective 
study of the Japanese multi-institutional database reported 
that PORT did not improve either OS (p = 0.172) or relapse-
free survival (p = 0.362) in stage III thymomas.12 Despite the 
value of the national large-scale analysis, the distributions of 
baseline clinicopathologic features, including age at diagnosis, 
tumor size, Masaoka stage, and completeness of surgery, were 
significantly different in the PORT and non-PORT groups. 
Contrary to stages II to III thymoma, in stage IV, clinical data 
on PORT were not sufficiently reported. Instead, the role of 
FIGURE 2.  Comparison of overall survival (A) 
and disease-specific survival (B) according to 
the receipt of postoperative radiotherapy after 
propensity score matching. PORT, postoperative 
radiotherapy.
TABLE 3.  Multivariate Analyses of Overall and Disease-specific Survival in the Matched Population
Variables
Overall Survival Disease-specific Survival
Hazard Ratio 95% CI
p Value
Hazard Ratio 95% CI
p Value
Age (yrs)
 <57 Reference
 ≥57 2.60 1.62–4.17 <0.001
Tumor extent
 Adjacent connective tissue Reference Reference
 Adjacent organs or structures 2.69 1.59–4.58 <0.001 3.55 1.44–8.73 0.006
 Further contiguous extension 2.15 1.04–4.43 0.039 4.15 1.44–11.96 0.009
PORT
 Yes Reference Reference
 No 1.98 1.27–3.09 0.003 2.64 1.32–5.29 0.006
CI, confidence interval; PORT, postoperative radiotherapy.
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chemotherapy as an adjuvant or neoadjuvant treatment strat-
egy has been investigated.28–30 Therefore, our results on the sur-
vival advantages in stages III to IV could contribute important 
knowledge of the clinical implications of PORT in thymomas.
Several large-scale studies have reported the survival 
outcomes of stages III to IV with or without PORT. Kondo 
and Monden31 reported on the Japanese multi-institutional 
analysis, and the authors found no role of PORT in totally 
resected stages III and IV thymomas. However, patient selec-
tion bias cannot be excluded, because no adjuvant therapy 
obtained significantly better survival compared with radio-
chemotherapy (p = 0.0353). In one previous SEER analy-
sis, PORT improved OS in a univariate analysis of stages 
III and IV (p = 0.04).13 Although this result was compatible 
with our study, its statistical significance was eliminated in 
a multivariate analysis. Interestingly, the increasing year of 
diagnosis was significantly associated with improved OS (the 
years of 1973–1983 versus 1984–1993 versus 1994–2003). 
In this study, the survival benefits of PORT irrespective of 
other clinicopathologic factors were initially reported. We 
suggest that the propensity score matching and more recently 
diagnosed patients analyzed in this study might be attributed 
to the significant results. In fact, the Chinese group recently 
demonstrated that the three-dimensional conformal/inten-
sity-modulated RT technique seemed to be associated with 
longer survival and reduced relapse rates compared with con-
ventional RT.32 Continued research is necessary to estimate 
the survival advantages of PORT in the modern era of RT.
This study has several limitations. Pathologic resection 
margins were not reported in the SEER database, limiting the 
analysis of microscopic resection margins. In addition, the reg-
istry did not include any information on patients’ performance 
status, combined morbidity, or use of chemotherapy. With the 
limited surgery-related information, the detailed surgical tech-
niques and the degree of surgical skill of each institution were 
not obtainable. Regarding RT methods, the total radiation dose, 
fraction size, extent of treatment field, and radiation techniques 
were not described. Because other unmeasured potential con-
founders in the database could not be excluded, the propensity 
score matching did not fully eliminate the limitations of the 
FIGURE 3.  Overall survival and disease-specific 
survival of the stage IIB (A and B), stage III  
(C and D), and stage IV (E and F) with or 
 without postoperative radiotherapy. PORT, 
 postoperative radiotherapy.
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retrospective design. The present analyses included patients 
with relatively shorter follow-up durations, and additional anal-
yses with longer follow-ups are essential.
Although this study suggested the significant impact of 
RT-induced local tumor control on patients’ survival outcomes, 
we could not assess the extent of irradiation field and its relevance 
to failure patterns or survival in the nation-wide population. A 
retrospective study recently analyzed 156 patients with stages 
II to IV thymomas undergoing involved field RT after surgical 
resection.33 In-field failures were observed in only five patients, 
but out-of-field recurrences were also reported in 22 patients. 
These results were similar with the prior investigations,34–36 and 
the authors pointed out the need of more discussions on the 
optimal RT fields to reduce pleural recurrences. Concerning 
RT-related pulmonary or cardiac toxicities, much extended irra-
diation fields could not be recommended in clinical practices. 
Nevertheless, there is the potential for the extended irradiation 
fields or RT dose escalation using the modern RT techniques. To 
improve long-term outcomes of nonlocalized thymomas, further 
studies to optimize RT methods are necessary.
Based on the SEER registry, this propensity-matched 
analysis firstly ascertained the independent survival advantages 
of PORT in nonlocalized thymomas. Our significant results 
seem markedly important in that other previous investigations 
have been usually inconclusive. In subgroup analyses accord-
ing to Masaoka stage, better survival outcomes with PORT 
were verified in stages III and IV. Considering the poor prog-
nostic impacts of no receipt of PORT and more invasive tumor 
extents, we suggest that the use of RT after surgical resection 
is recommended in patients with stages III to IV thymomas. 
Further investigations are necessary to identify the detailed 
treatment indication of PORT in nonlocalized thymomas.
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